Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0348321 (Haemophilus)
 15,372 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This report was prompted by the isolation of Haemophilus influenza from cultures of specimens from genital sites in 11 patients. All cervical, vaginal, and urethral specimens submitted to the Section of Clinical Microbiology Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, for bacterial culture are routinely inoculated onto blood agar, eosinmethylene blue (EMB) agar, chocolate blood agar, Columbia colistin-nalidixic acid (CNA) blood agar, and unless previously directly inoculated by the attending physician, modified Thayer-Martin medium. As a rule, identification and reporting of isolates is limited to Neisseria gonorrhoeae, N. meningitidis, Gardnerella vaginalis, beta-hemolytic streptococci, Listeria monocytogenes, and Staphylococcus aureus. Cultures for anaerobic bacteria are restricted to endocervical or endometrial aspirates which are submitted to the laboratory in anaerobic transport vials. Cultures for fungi, Chlamydia trachomatis, and Ureaplasma urealyticum are performed by specific request, as is miscroscopic examination for Trichomonas vaginalis. Haemophilus influenzae was identified with the porphyrin test according to the Kilian's taxonomic system. Genital tract specimens from 11 patients yielded H. influenzae in pure or predominant culture. 9 patients were females, of whom 4 had vaginitis, usually with a yellowish, foul smelling discharge. 2 had IUD-related endometritis and parametritis, 1 had an incomplete septic abortion, and 1 had probable urethral syndrome. 2 males had urethritis. Cultures were negative for N. gonorrhoeae in every case and for C. trachomatis in the 6 patients whose specimens were cultured for this agent. Only 2 women -- 1 with vaginitis and 1 with probable urethral syndrome -- had G. vaginalis in cultures of vaginal secretions, while U. urealyticum was isolated from vaginal or cervical secretions of 3 of 4 women cultured for the organism.
 ...
PMID:Haemophilus influenzae in genitourinary tract infections. 660 36

New selective and differential human blood bilayer agar media with Tween 80 (HBT medium) or without Tween 80 (HB medium), developed for the isolation of Gardnerella (Haemophilus) vaginalis, permitted significantly higher G. vaginalis isolation rates than have been obtained for other media used for this purpose. HB medium consists of a basal layer of Columbia agar base containing colistin and naladixic acid with added amphotericin B and an overlayer of the same composition plus 5% human blood. HBT agar also contains Proteose Peptone No. 3 (Difco Laboratories) and Tween 80 in the basal layer and the overlayer. Both Tween 80 and the bilayer composition enhanced G. vaginalis production of human blood hemolysis, permitting detection of this organism even in the presence of heavy growth of other vaginal flora. The use of HB or HBT medium thus permitted the demonstration that G. vaginalis was present in vaginal fluid from a large percentage (up to 68%) of normal women. However, the concentration of G. vaginalis was found by semiquantitative analysis to be significantly higher in vaginal fluid from women with nonspecific vaginitis than in fluid from normal women.
 ...
PMID:Selective differential human blood bilayer media for isolation of Gardnerella (Haemophilus) vaginalis. 676 66

The susceptibilities of strains of Gardnerella vaginalis (Haemophilus vaginalis), Neisseria gonorrhoeae, and Bacteroides fragilis to metronidazole and its principal oxidative metabolites (1-[2-hydroxyethyl]-2-hydroxymethyl-5-nitroimidazole) ("hydroxy" metabolite) and 1-acetic acid-2-methyl-5-nitroimidazole ("acid" metabolite), were compared by determinations of the minimal inhibitory concentrations (MICs) of these compounds. Against ten strains of G. vaginalis, the hydroxy metabolite was the most active (median MIC, 2 microgram/ml); the median MICs of metronidazole and of the acid metabolite were 8 and 64 microgram/ml, respectively. The hydroxy metabolite was also the most active against 15 strains of N. gonorrhoeae (median MIC, 32 microgram/ml). In contrast, metronidazole was the most active against ten strains of B. fragilis (median MIC, 1 microgram/ml); the hydroxy and acid metabolites had median MICs of 2 and 64 micrograms/ml, respectively. These results indicate that in the treatment of G. vaginalis-associated vaginitis with metronidazole, the hydroxy metabolite may contribute a significant antimicrobial effect, in view of its excellent activity in vitro.
 ...
PMID:Relative susceptibilities of Gardnerella vaginalis (Haemophilus vaginalis), Neisseria gonorrhoeae, and Bacteroides fragilis to Metronidazole and its two major metabolites. 677 87

To study the cause of nonspecific vaginitis, we analyzed vaginal fluid from normal women and from 53 women with nonspecific vaginitis, using quantitative anaerobic cultures and gas-liquid chromatography for short-chained organic-acid metabolites of the microbial flora. In normal vaginal fluid, lactate was the predominant acid, and the predominant organisms were lactobacillus and streptococcus species (lactate producers). In nonspecific vaginitis, lactate was decreased, whereas succinate, acetate, butyrate, and propionate were increased, the predominant flora included Gardnerella (Haemophilus) vaginalis (acetate producer), and anaerobes, which included bacteroides species (succinate producers) and peptococcus species (butyrate and acetate producers). After metronidazole therapy, symptoms and signs of nonspecific vaginitis cleared, butyrate and propionate disappeared, and lactate and lactate-producing organisms became predominant. We conclude that certain anaerobes act with G. vaginalis as causes of nonspecific vaginitis, and that a high ratio of succinate to lactate in vaginal fluid is a useful indicator in the diagnosis of this condition.
 ...
PMID:Anaerobic bacteria in nonspecific vaginitis. 696 62

Four antimicrobial agents (triple sulfa cream, doxycycline, ampicillin, and metronidazole) were studied by double-blind techniques to determine their effectiveness in the treatment of Hemophilus vaginalis vaginitis, documented by vaginal culture in 96 patients. Cure was confirmed by negative vaginal cultures 7 weeks after the start of therapy. Metronidazole proved to be effective in 20 of 22 couples (90.9%) treated. Sulfa cream, doxycycline, and ampicillin were effective in 47.8 to 63.6% of patients treated.
 ...
PMID:Treatment of Hemophilus vaginalis vaginitis. 697 18

This paper provides an abbreviated review of developments related to Haemophilus vaginalis vaginitis since its original description a quarter of a century ago. My intervening years of interest and research in the field of vulvovaginal infections have served to further confirm the originally published concepts regarding this highly prevalent, precisely defined, readily recognizable, and aesthetically objectionable vaginal disease. An occasional investigator still questions the pathogenicity of the causative short gram-negative bacillus. The only remaining major controversy, however, concerns the taxonomic position of the organism. The evidence is that it belongs neither to the genus Haemophilus nor to the genus Corynebacterium.
 ...
PMID:Haemophilus vaginalis vaginitis after twenty-five years. 699 Jul 64

The physiology and flora of the normal vagina and the more common causes and associated treatments of vaginitis are reviewed. Vaginitis encompasses a group of diseases causing inflammatory changes in the vagina and vulva. Treatment of the various vaginitides requires accurate diagnosis, which is hampered by difficulties in culturing pathogens and in resolving the pathogenicity of various organisms. The ability of the body to withstand vaginitis is affected by physiologic changes within the vagina. The vaginitides and associated treatments reviewed include candidiasis and trichomoniasis; Hemophilus vaginalis and other bacterial vaginitis; and Herpes hominis, chlamydial, and atropic vaginitis.
 ...
PMID:Treatment of vaginitis. 699 78

In two general practices in Perth, Western Australia, the most common microbiological causes of vaginal discomfort in 368 patients were Candida albicans. Gardnerella (Haemophilus) vaginalis, Trichomonas vaginalis and bacteroides fragilis. Amongst patients with abnormal vaginal odour, with or without vaginitis, the most common cause of odour was G. vaginalis. The writers advocate that heavy growths of group B streptococci, Escherichia coli, and enterococci should be considered to be the possible cause of vaginal discomfort. This reinforces the need for care in collection, transportation, and microbiological examination of swabs of the female genital tract. as well as in the clinical interpretation of these reports.
 ...
PMID:Vaginitis associated with vaginal malodour. 702 28

The review of the treatment of bacterial vaginosis parallels the history of this syndrome. Before the syndrome was defined, treatment was local and nonspecific. Gardner and Dukes defined nonspecific vaginitis in 1955 as an infection caused by Haemophilus vaginalis. Therapy was directed toward this aerobic "pathogen" and included oral tetracycline and a triple sulfa vaginal cream. Subsequent studies indicated success with this regimen as well as with ampicillin, a drug with good aerobic activity. Since 1977, studies have shown the importance of anaerobes in this clinical syndrome. Both metronidazole and clindamycin have been found to have clinical success. The clinical definition of the disease makes evaluation of treatment difficult, because it includes women without symptoms.
 ...
PMID:Historical review of the treatment of bacterial vaginosis. 835 49

Trovafloxacin is a fluoroquinolone antibacterial agent with a broad spectrum of activity. Trovafloxacin has similar or 2-fold lower activity than ciprofloxacin against Enterobacteriaceae and Pseudomonas aeruginosa. Against Haemophilus influenzae and Moraxella catarrhalis, trovafloxacin has similar activity to ciprofloxacin. Other susceptible Gram-negative pathogens include Neisseria gonorrhoeae, Chlamydia trachomatis and mycoplasmas. The drug is active against Gram-positive bacteria and consistently displayed greater activity (2- to 8-fold) than ciprofloxacin against all staphylococci and streptococci tested; activity included methicillin-resistant staphylococci and penicillin-resistant Streptococcus pneumoniae. Trovafloxacin has some activity against vancomycin-resistant enterococci. Anaerobes such as Bacteroides and Clostridium spp. are also susceptible to trovafloxacin. Preliminary clinical data suggest that trovafloxacin is effective in the treatment of patients with upper and lower respiratory tract and uncomplicated urinary tract infections and infections caused by C. trachomatis or N. gonorrhoeae. The most frequently noted adverse event with trovafloxacin is dizziness which is reported in 11% of patients versus 3% of those receiving comparator agents. Other commonly reported events (> 1% of patients) are nausea, headache, vomiting, vaginitis and diarrhoea.
 ...
PMID:Trovafloxacin. 927 5


<< Previous 1 2 3 4 Next >>